Business
Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference
PHILADELPHIA, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will participate in a fireside chat during the Guggenheim Securities 2nd Annual Healthcare Innovation Conference on Wednesday, November 12, 2025 at 9:30 a.m. ET in Boston, MA. A live webcast of the event will be available
About this update from Passage Bio, Inc.
PHILADELPHIA, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will participate in a fireside chat during the Guggenheim Securities 2 nd Annual Healthcare Innovation Conference on Wednesday, November 12, 2025 at 9:30 a.m. ET in Boston, MA. A live webcast of the event will be available on the Investors & News section of Passage Bio’s website at investors.passagebio.com . A replay of the event will be available for 90 days following the event. About Passage Bio Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression. To learn more about Passage Bio and our steadfast commitment to protecting patients and families against loss in neurodegenerative conditions, please visit: passagebio.com . For further information, please contact: Investors: Stuart Henderson Passage Bio [email protected] Passage Bio Media: Mike Beyer Sam Brown Inc. Healthcare Communications 312.961.2502 [email protected]